Center for Beta Cell Therapy in Diabetes and ViaCyte announce start of European trial
The Center for Beta Cell Therapy in Diabetes and ViaCyte announced that a human stem cell-derived product candidate has been implanted in type 1 diabetes patients at a subtherapeutic dose. These are the first patients in Europe to receive PEC-Direct to replace lost insulin-producing beta cells. January 21, 2019